Assessment of claims of improved prediction beyond the Framingham risk score.
about
Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposalPrognostic effect size of cardiovascular biomarkers in datasets from observational studies versus randomised trials: meta-epidemiology studyStrengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration.Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaborationHigh-sensitivity ST2 for prediction of adverse outcomes in chronic heart failureImproved prediction of complex diseases by common genetic markers: state of the art and further perspectivesClassical and novel biomarkers for cardiovascular risk prediction in the United StatesDiagnostic and prognostic prediction modelsIs prevention a fantasy, or the future of medicine? A panoramic view of recent data, status, and direction in cardiovascular prevention.Development of a cardiovascular risk score for use in low- and middle-income countriesReporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration.Providing clinicians with a patient's 10-year cardiovascular risk improves their statin prescribing: a true experiment using clinical vignettes.Development of a multi-institutional cohort to facilitate cardiovascular disease biomarker validation using existing biorepository samples linked to electronic health records.Critical appraisal and data extraction for systematic reviews of prediction modelling studies: the CHARMS checklist.Modern modelling techniques are data hungry: a simulation study for predicting dichotomous endpoints.The Net Reclassification Index (NRI): a Misleading Measure of Prediction Improvement Even with Independent Test Data SetsCigarette smoking exacerbates the adverse effects of age and metabolic syndrome on subclinical atherosclerosis: the Bogalusa Heart StudyStatistical evaluation of adding multiple risk factors improves Framingham stroke risk scorePredicting coronary heart disease events in women: a longitudinal cohort study.A coronary heart disease prediction model: the Korean Heart Study.Assessing the incremental predictive performance of novel biomarkers over standard predictors.Does C-reactive protein add prognostic value to GRACE score in acute coronary syndromes?Evaluation of markers and risk prediction models: overview of relationships between NRI and decision-analytic measures.Comparative clinical- and cost-effectiveness of candesartan and losartan in the management of hypertension and heart failure: a systematic review, meta- and cost-utility analysis.Does present use of cardiovascular medication reflect elevated cardiovascular risk scores estimated ten years ago? A population based longitudinal observational studyStrengthening the reporting of Genetic RIsk Prediction Studies: the GRIPS Statement.Utility of Framingham risk score in urban emergency department patients with asymptomatic hypertension.The emergence of translational epidemiology: from scientific discovery to population health impact.How to interpret a small increase in AUC with an additional risk prediction marker: decision analysis comes through.Adding multiple risk factors improves Framingham coronary heart disease risk scores.Framingham risk score and alternatives for prediction of coronary heart disease in older adults.Thermal provocation to evaluate microvascular reactivity in human skin.Value of the first post-transplant biopsy for predicting long-term cardiac allograft vasculopathy (CAV) and graft failure in heart transplant patientsPredictors of first lifetime onset of major depressive disorder in young adulthood.Weak prediction power of the Framingham Risk Score for coronary artery disease in nonagenarians.Coronary artery calcium score and risk classification for coronary heart disease prediction.Genetic cardiovascular risk prediction: will we get there?Update on the NCEP ATP-III emerging cardiometabolic risk factors.The diagnostic performance of the Mass Restricted (MR) score in the identification of microbial invasion of the amniotic cavity or intra-amniotic inflammation is not superior to amniotic fluid interleukin-6.Obstructive sleep apnea and risk of cardiovascular events and all-cause mortality: a decade-long historical cohort study.
P2860
Q24288920-0CA2F29F-E7C7-4415-B234-626EEE8E140AQ24289043-1242BA9F-87E5-4352-9CC6-365A329AAA25Q24289354-AEB33C28-EC2E-4F22-93F2-D66C63433563Q24289476-35AF6D6C-BEF1-43D9-9AFD-C4A8BE7764A5Q24610732-269CF142-A6AB-44BD-8094-EBEF1CE457E1Q26770167-23824D98-447E-497C-A678-C36099843F85Q26824026-9306B13F-F827-4BE9-A31C-D5C7D64DB69FQ26827577-7220D8CF-6744-4584-B3BA-BEEF3B6B1282Q30397875-0F3F718F-5918-47D7-A322-27FC9BEFF5C3Q30501026-1E4A4C02-7F32-46C2-8345-5046F8F973C6Q30514241-3F41C596-613A-4B3D-9285-B9825E1302D9Q30571866-DFD87913-9ACF-410F-86E8-3C8F2894DCD7Q30574994-2A623627-FE77-4337-B0E5-EE3F3F595105Q30860218-2226636E-17DF-4979-8510-225E258BF7BAQ30881531-C09C2957-D504-428F-9AE9-9B3B6C26D0DBQ31011669-A762212A-C1FF-446C-84D8-294969D4A911Q33560324-CFD41405-B5FD-4D10-BFF7-D79A952DE444Q33564681-9C0DE12F-8EE0-41BA-AE90-691289A8B2A9Q33605432-825726D8-ECB9-486B-9760-5C6A96D4CDB8Q33691318-C6BD2CCB-B62B-48C5-BA93-01122E466D23Q33717407-5B0ECBB1-5496-40AC-9B67-6731EA00665EQ33733405-91BE335E-E0B6-413B-8BB6-9768EC310542Q33791377-C28E3575-9D3F-460C-AFA7-4B169C8EC516Q33809879-CC76B580-D1AB-46B4-B188-62901DC9878AQ33834899-E7A8C6DB-96A7-4C2C-91FC-C8B1058D0689Q33851304-6E49D626-2393-4CF5-A58F-28C0A77E4D0DQ33959468-63469884-C406-4BC4-A129-55881B925246Q34082166-C0D9BAE7-9F01-4CF4-8D6B-F8A9BA7109AEQ34143220-A074615E-3FF3-441B-84DE-40E85DC00DD8Q34173016-498B314A-10B9-4420-A5EE-9BC2373D7BF7Q34217860-3E339AAB-3580-4536-8113-4CCDB703CE3EQ34236414-45816DF3-43D9-4157-820A-279BB65FABC4Q34257142-613031EB-207B-4E77-BD1C-4BA8CC9EB765Q34378461-C9376046-99DC-457C-B559-2875C9756796Q34506768-955DF7C3-C311-491F-AC0A-8B38E0204C28Q34552221-61579749-4D4F-476A-AC7C-1A0C7CF4FACBQ34787709-79CBCC42-A783-4BF6-95DD-0B23DB61BCABQ34811590-6E68C251-AF61-4734-B79F-89FCDAE5713BQ34985972-ACB14BC2-2E13-47C8-A18E-95BF0462CB96Q35087597-29AF9259-C857-4F3F-B7A3-6803F33D3F80
P2860
Assessment of claims of improved prediction beyond the Framingham risk score.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Assessment of claims of improved prediction beyond the Framingham risk score.
@ast
Assessment of claims of improved prediction beyond the Framingham risk score.
@en
type
label
Assessment of claims of improved prediction beyond the Framingham risk score.
@ast
Assessment of claims of improved prediction beyond the Framingham risk score.
@en
prefLabel
Assessment of claims of improved prediction beyond the Framingham risk score.
@ast
Assessment of claims of improved prediction beyond the Framingham risk score.
@en
P356
P1476
Assessment of claims of improved prediction beyond the Framingham risk score.
@en
P2093
George Liberopoulos
P304
P356
10.1001/JAMA.2009.1757
P407
P577
2009-12-01T00:00:00Z